Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 for acute agitation in schizophrenia
NCT03708315Phase 1Completed
- Sponsor
- Yale University
- Start
- Mar 2020
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dexmedetomidine in schizophrenia and schizoaffective disorder (2 arms), sponsored by Yale University. Primary endpoints: Positive and Negative Symptom Scale Excited Component, Skin conductance response at 11 hours and 4 more. Started Mar 2020; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT03708315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708315.